Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

导出 OA

翻译打印收藏纠错

第一作者： Yong-Chen,Lu

第一单位： Yong-Chen Lu, Linda L. Parker, Tangying Lu, Zhili Zheng, Mary Ann Toomey, Donald E. White, Xin Yao, Yong F. Li, Paul F. Robbins, Steven A. Feldman, Christopher A. Klebanoff, Stephanie L. Goff, Richard M. Sherry, Udai S. Kammula, James C. Yang, and Steven A. Rosenberg, National Cancer Institute, Bethesda, MD; Pierre van der Bruggen, Ludwig Institute for Cancer Research; De Duve Institute, Université Catholique de Louvain, Brussels; and Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wallonia, Belgium; Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy, New York, NY.

作者： Yong-Chen,Lu ^[1] ; Linda L,Parker ^[1] ; Tangying,Lu ^[1] ; Zhili,Zheng ^[1] ; Mary Ann,Toomey ^[1] ; Donald E,White ^[1] ; Xin,Yao ^[1] ; Yong F,Li ^[1] ; Paul F,Robbins ^[1] ; Steven A,Feldman ^[1] ; Pierre,van der Bruggen ^[1] ; Christopher A,Klebanoff ^[1] ; Stephanie L,Goff ^[1] ; Richard M,Sherry ^[1] ; Udai S,Kammula ^[1] ; James C,Yang ^[1] ; Steven A,Rosenberg ^[1]

作者单位： Yong-Chen Lu, Linda L. Parker, Tangying Lu, Zhili Zheng, Mary Ann Toomey, Donald E. White, Xin Yao, Yong F. Li, Paul F. Robbins, Steven A. Feldman, Christopher A. Klebanoff, Stephanie L. Goff, Richard M. Sherry, Udai S. Kammula, James C. Yang, and Steven A. Rosenberg, National Cancer Institute, Bethesda, MD; Pierre van der Bruggen, Ludwig Institute for Cancer Research; De Duve Institute, Université Catholique de Louvain, Brussels; and Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wallonia, Belgium; Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy, New York, NY. ^[1]